Roche and Trimeris apply for FDA approval of Fuzeon
BY Advocate.com Editors
September 19 2002 12:00 AM ET
Drugmakers Roche and Trimeris on Tuesday applied to the Food and Drug Administration for approval of their new anti-HIV drug Fuzeon, formerly known as T-20, The Wall Street Journal reports. The companies requested a priority six-month review for the compound and hope to have it on the market in the first quarter of 2003. Fuzeon is the drug in a new class of medications called entry or fusion inhibitors, which work outside the body's cells by preventing HIV from attaching to and infecting them. The FDA application requested review for Fuzeon as part of combination therapy to treat HIV infection.
Roche and Trimeris officials say the drug is designed to treat patients whose HIV has become resistant to other antiretroviral drugs. The companies plan to file for European Union approval of the drug by the end of the month. Analysts say that a year's supply of the drug, which must be
injected, will cost between $10,000 and $15,000.
Sign Up For Email Updates
- Arts & Entertainment Week in Beef: Ben Cohen, Frank Ocean, Hugh Jackman, and More Shirtless Celebs 2 hours 39 min ago
- Sports Griner: Baylor Coach Enforced Closet Policy 2 hours 42 min ago
- Politicians Gay Activists Interrupt Marco Rubio Speech 2:03 PM
- Hate-crimes WATCH: Vigil for Hate Crime Victim Mark Carson 1:01 PM
- Television WATCH: The Cure for Gay Wedding-Related Depression 12:39 PM
- Television WATCH: Did Stefon Marry Seth Meyers or Anderson Cooper? 12:32 PM
- Crime Gay Man Gunned Down in NYC Street, Dies UPDATED: May 18 2013 7:24 PM